[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"irritable-bowel-syndrome---diarrhoea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:irritable-bowel-syndrome---diarrhoea":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,71,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100650688","kimchi-powder-on-gut-health-100650688",false,"NCT07749092","Kimchi Powder on Gut Health","The Effect of Kimchi Powder Supplementation on Gut Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (KIMCHI-GUT Trial)","Inclusion Criteria:\n\n* Adults, male or female, aged 20 to 70 years\n* Body mass index of 25 kg\u002Fm2 or more and less than 30 kg\u002Fm2\n* Meeting the Rome IV criteria for diarrhea-predominant irritable bowel syndrome (IBS-D), defined as Bristol Stool Form Scale type 6 or 7 in 25% or more of bowel movements from 2 weeks before screening through the day of the screening visit\n* No inflammatory bowel disease or malignancy\n* Provided written agreement to refrain from consuming kimchi-containing foods for the duration of the study (approximately 2 months)\n\nExclusion Criteria:\n\n* Drug-induced constipation\n* Constipation secondary to another condition, such as diabetes mellitus or thyroid disease\n* History of intra-abdominal surgery other than appendectomy (including gastrectomy, gastric bypass, gallbladder or biliary tract surgery, pancreatectomy, bowel resection with particular reference to the ileum, and colorectal surgery or insertion procedures)\n* Uncontrolled hypertension (resting blood pressure 160\u002F100 mmHg or higher)\n* Uncontrolled diabetes mellitus (fasting blood glucose 160 mg\u002FdL or higher)\n* Uncontrolled hypothyroidism or hyperthyroidism\n* AST or ALT concentration 3 times or more the upper limit of the reference range of the testing laboratory\n* Creatinine concentration 2 times or more the upper limit of the reference range of the testing laboratory\n* Severe cardiovascular or cerebrovascular disease or malignancy within the previous 6 months\n* Psychiatric disorder such as severe affective disorder, schizophrenia, or substance use disorder, or current use of related psychiatric medication (intermittent use for sleep disturbance is permitted)\n* Severe alcohol use disorder\n* Heavy smoking (20 cigarettes per day or more)\n* Hypersensitivity to the main ingredient or components of the study food\n* Severe gastrointestinal symptoms such as heartburn or dyspepsia\n* Use of medications or foods that may affect the study results, including kimchi and probiotics\n* For female volunteers, suspected pregnancy, lactation, or plan to become pregnant during the study period\n* Participation in another drug clinical trial within one month prior to the screening date, or planned participation\n* Judged unsuitable for participation by the principal investigator for reasons other than those listed above","ALL","20 Years","70 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The investigators will conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Kimchi powder supplementation on gut health in adults with diarrhea-predominant irritable bowel syndrome (IBS-D) for 8 weeks.",[27],"Irritable Bowel Syndrome - Diarrhoea",[29,30,31,32],"Kimchi","Irritable bowel syndrome - Diarrhea","Gut microbiome","Fermented food","RECRUITING","2026-08-01",{"date":36,"type":37},"2026-08-06","ACTUAL",{"date":39,"type":21},"2026-08-03",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"Pusan National University Yangsan Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100601712","phase-2-effect-of-ebastine-in-patients-with-diarrhea-predominant-irritable-bowel-syndrome-100601712","NCT07114055","Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome","Inclusion criteria\n\n* Age 18 and above\n* Patients who meet the Rome IV criteria for IBS-D.\n\nExclusion criteria\n\n* Presence of alarm features: anemia, weight loss, per rectal bleeding, nocturnal frequency, and family history of colonic cancer\n* History of major gastrointestinal surgery\n* Medical disease that affect the digestive system, such as uncontrolled diabetes, hyperthyroidism, hypothyroidism\n* Pregnant and lactating women\n* Vehicle drivers, mechanical operators and aerial operators\n* Drug abuse or alcohol abuse","18 Years",{"count":54,"type":21},60,[56,57],"PHASE2","PHASE3","The goal of this clinical trial is to assess and compare the effect of ebastine and placebo in improving symptoms in patients with diarrhea predominant IBS. It will also assess about the safety of drugs ebastine and placebo by recording the patient reported adverse events. The main questions it aim to answer are:\n\nDoes drug ebastine and placebo has any effect on patients with IBS-D? What medical problems do participants have when taking drug ebastine and placebo? Researcher will compare effect of drug ebastine and placebo .\n\nParticipant will:\n\nTake drug ebastine 20 mg at night and placebo once daily at night every day for 8 weeks along with lifestyle modifications. After that all two groups will visit the hospital 4 weekly, and their symptoms will be assessed by IBS symptom severity score (IBS-SSS) at baseline, week 4 and week 8. Additionally, patient reported adverse events will be documented.",[27],[61],"Ebastine","2025-08-18",{"date":64,"type":37},"2025-08-20",{"date":66,"type":37},"2025-08-15",{"date":68,"type":21},"2026-07",{"name":70,"class":44},"Md. Hazrat Ali",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100597645","phase-4-fengliao-changweikang-for-diarrhea-predominant-irritable-bowel-syndrome-n-of-1-trial-100597645","NCT07061184","Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial","The Efficacy of Fengliao Changweikang Keli for Patients With Diarrhea-predominant Irritable Bowel Syndrome: Study Protocol for a Multicenter, Randomized, Placebo-controlled N-of-1 Trial","Inclusion Criteria:\n\n1. Aged between 18 and 75 years.\n2. Mild to moderate IBS-D patients, with IBS Severity Scoring System (IBS-SSS) scores of 75 to 300 points\\[14\\].\n3. Ability to complete questionnaires and provide written informed consent.\n4. Current use of IBS medications (probiotics, antibiotics, antispasmodic, antidiarrheal and neuromodulators) should be prescribed on a stable dose at least 30 days prior to enrollment, and have no plan to change the dose, diet or lifestyle.\n5. Normal blood cell count, liver function, creatinine and urea levels within the last 2 weeks.\n\nExclusion Criteria:\n\n1. History of organic gastrointestinal diseases such as inflammatory bowel disease, celiac disease and malignancy.\n2. Scores of IBS-SSS \\> 300 points or IBS-SSS \\\u003C 75 points.\n3. History of severe heart, kidney or liver diseases.\n4. Pregnant or breastfeeding.\n5. Current alcohol or drug abuse.","75 Years",{"count":80,"type":21},50,[82],"PHASE4","Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder, with characteristics of defecation related abdominal pain and diarrhea. Routine treatment strategy for IBS-D is symptom-based with unsatisfactory results, while there is a growing interest in complementary and alternative medicine such as Traditional Chinese Medicine. However, lack of high-quality evidences being the obstacle for its development.\n\nThis study aims to evaluate the efficacy of Fengliao Changweikang Keli (FLCWK) on symptoms and health-related quality of life in mild to moderate IBS-D patients.\n\nAfter 2-week run-in period, each participant will be randomized to a sequence of six 4-week double-blind treatment periods of FLCWK 8 g three times daily or placebo, separated by 2-week washout periods.",[27,85,86,87],"Traditional Chinese Medicine (TCM)","N of 1 Study Design","Efficacy and Safety","NOT_YET_RECRUITING","2025-07-02",{"date":91,"type":37},"2025-07-11",{"date":93,"type":21},"2025-11",{"date":95,"type":21},"2028-05",{"name":97,"class":44},"Peking Union Medical College Hospital",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":45},"100575971","effect-of-food-derived-active-components-on-digestive-tract-health-in-adults-with-irritable-bowel-syndrome-100575971","NCT06779214","Effect of Food-derived Active Components on Digestive Tract Health in Adults with Irritable Bowel Syndrome","Inclusion Criteria:\n\n* met the Western Medicine Rome IV diagnostic criteria for diarrheal IBS\n* 18 and 60 years old\n* subjects voluntarily sign informed consent forms.\n\nExclusion Criteria:\n\n* Having a disease that may affect the gut microbiome (e.g., inflammatory bowel disease, celiac disease, diabetes)\n* Abdominal pain or diarrhea due to organic disease\n* Patients with abdominal surgery\n* Patients with serious mental illness and complications of heart, brain, liver, kidney and other systems\n* Unable to communicate normally or skilled in the use of communication equipment\n* Having serious mental problems or taking related drugs\n* Drug or alcohol abusers\n* People with special diets (such as vegetarians) or eating disorders or are receiving therapeutic dietary interventions\n* Had used antibiotics, probiotics, other drugs that may affect the study\n* Participants who are participating in other clinical trials\n* Pregnant or lactating women","60 Years",{"count":106,"type":21},180,[24],"The goal of this clinical trial is to learn if Bifidobacterium. animalis subsp.\n\nLactis A6 Strain or resveratrol to improve the symptoms of diarrhea-predominate irritable bowel syndromes (IBS-D). The main questions it aims to answer are:\n\n1. Does Bifidobacterium animalis subsp.Lactis A6 Strain or resveratrol improve the symptoms of IBS-D.\n2. What is the optimal intervention dose of Bifidobacterium. animalis subsp.Lactis A6 Strain or resveratrol to improve IBS-D\n\nResearchers will compare Bifidobacterium. animalis subsp.Lactis A6 Strain or resveratrol interventions to placebo (one look-alike sunbstance that contains no interventions substance) to see if Bifidobacterium. animalis subsp.Lactis A6 Strain or resveratrol relief the symptoms of patients with IBS-D.\n\nParticipants will:\n\n1. Take Bifidobacterium. animalis subsp.Lactis A6 Strain or resveratrol every day for 30 days.\n2. Visit the clinic once every 15 days for checkups and tests.",[27],[111,112,113],"Diarrhea-predominate Irritable bowel syndrome","probiotics","polyphenols","2025-01-12",{"date":116,"type":37},"2025-01-16",{"date":118,"type":21},"2025-02-28",{"date":120,"type":21},"2025-12-31",{"name":122,"class":44},"Peking University"]